loading page

Renin-Angiotensin-Aldosterone-System Blocking Drugs in Patients with SARS-CoV-2 - Systematic Review and Meta-Analysis
  • +3
  • Chang Chu,
  • Shufei Zeng,
  • Ahmed Hasan,
  • Carl-Friedrich Hocher,
  • Bernard Kraemer,
  • Berthold Hocher
Chang Chu
Charite Universitatsmedizin Berlin
Author Profile
Shufei Zeng
Charite Medical Faculty Berlin
Author Profile
Ahmed Hasan
University of Potsdam
Author Profile
Carl-Friedrich Hocher
University of Heidelberg
Author Profile
Bernard Kraemer
University of Heidelberg, Medical Faculty Mannheim
Author Profile
Berthold Hocher
University of Heidelberg, Medical Faculty Mannheim
Author Profile

Abstract

Background and Purpose: COVID-19 patients treated with RAAS blockers are among the patients at highest risk of poor outcome. ACE2 is the functional receptor for SARS-CoV-2. Animal studies suggest that RAAS blockers might increase the expression of ACE2 and potentially increase the risk of SARS-Cov-2 infection. Experimental Approach and Key Results: The effect of ACE inhibitor treatment on the incidence of pneumonia in non-COVID-19 patients was analyzed in 25 studies (330,780 patients). ACE inhibitor use was associated with a 27% reduction of pneumonia risk (OR: 0.73, p<0.001). Pneumonia related death cases in ACE inhibitor treated non-COVID-19 patients were reduced by 27% (OR: 0.73, p=0.004). ARB treatment was analyzed in 10 studies (275,621 non-COVID-19 patients). The risk of pneumonia was not different between patients who did or did not use ARBs. Pooled results from 16 studies in 22,333 COVID-19 patients showed that COVID-19 related server adverse clinical outcomes (admission to ICU, need for assisted ventilation or death) were reduced by 26% when using RAAS blocking agents (OR=0.74, p=0.04). Pooled results from 10 studies in 11,514 COVID-19 patients showed that RAAS blockede reduces all-cause mortality by 41% (OR=0.59, p=0.01). Conclusion and Implications: Given the weak evidence coming from animal studies and the clear beneficial data of ACE inhibition in non-COVID-19 patients and the promising data in COVID-19 patients, the use of RAAS blocking agents in patients with SARS-CoV-2 infection is justified and should be maintained. Further clinical studies analysing ARBs and ACE inhibitors separately in COVID-19 patients are needed.

Peer review status:POSTED

08 Jun 2020Submitted to British Journal of Pharmacology
09 Jun 2020Assigned to Editor
09 Jun 2020Submission Checks Completed